S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NYSE:DPLO

Diplomat Pharmacy (DPLO) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$4.00
$4.01
50-Day Range
$4.00
$4.00
52-Week Range
$2.43
$14.46
Volume
744,968 shs
Average Volume
545,194 shs
Market Capitalization
$304 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DPLO stock logo

About Diplomat Pharmacy (NYSE:DPLO) Stock

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.


DPLO Stock News Headlines

Arusha Youth Sparkles in Diplomat Golf
New gold-backed currency could kill the Dollar
Rumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the price
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
DPLO_old Historical Data
See More Headlines
Receive DPLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diplomat Pharmacy and its competitors with MarketBeat's FREE daily newsletter.

DPLO Company Calendar

Last Earnings
11/12/2019
Today
9/25/2023

Industry, Sector and Symbol

Industry
Drug Stores & Proprietary Stores
Sub-Industry
N/A
Fax
N/A
Employees
2,335
Year Founded
N/A

Profitability

Net Income
$-302,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.49 billion
Cash Flow
$4.60 per share
Book Value
$6.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$304 million
Optionable
Optionable
Beta
0.82
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Brian Thomas Griffin (Age 60)
    CEO & Chairman
  • Mr. Philip R. Hagerman (Age 67)
    Co-Founder & Chairman Emeritus
  • Mr. Daniel Paul Davison
    CFO & Treasurer
  • Mr. Dave Loschinskey (Age 48)
    Chief Operating Officer
  • Ms. Terri Anne Powers
    VP of Investor Relations













DPLO Stock - Frequently Asked Questions

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $2.15. The business earned $1.30 billion during the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a negative trailing twelve-month return on equity of 12.15% and a negative net margin of 12.47%. The business's revenue for the quarter was down 5.3% on a year-over-year basis.

What other stocks do shareholders of Diplomat Pharmacy own?
What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $4.00.

How much money does Diplomat Pharmacy make?

Diplomat Pharmacy (NYSE:DPLO) has a market capitalization of $304 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis.

How many employees does Diplomat Pharmacy have?

The company employs 2,335 workers across the globe.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The official website for the company is www.diplomatpharmacy.com. The company can be reached via phone at 888-720-4450 or via email at tpowers@diplomat.is.

This page (NYSE:DPLO) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -